# Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder

> **NCT00454740** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 441 (actual)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** solifenacin succinate

## Key facts

- **NCT ID:** NCT00454740
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 441 (ACTUAL)
- **Last updated:** 2014-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454740, "Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00454740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*